Successful start of the clinical validation study of COLODETECT®, a blood-based diagnostic test for early detection of colorectal cancer by PROALT.View more.
PROALT attended the 9th International Biotechnology Meeting, BIOSPAIN 2018. Seville, Spain 25-27 September. View more.
PROALT attended the BIO International Convention 2018. Philadelphia, PA (USA) 3-6 June. View more.
PROALT announces partnership with Fusion Antibodies to develop humanized antibodies for therapy of metastatic colon cancer.View more.
PROALT attended the 12th BIOEUROPE SPRING conference and partnering event. Amsterdam (The Netherlands) 12-14 March. View more.
PROALT attended the 11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry, Zurich (Switzerland) 26-27 February. View more.
PROALT nominated for the Innovation Award, presents its colorectal cancer diagnostic and therapeutic projects at the eHealth Venture Summit 2017 in November 14th, MEDICA 2017. Düsseldorf (Germany) 13-16 November.View more.
PROALT attends AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics. Philadelphia (PA) from 26th to 30th October.View more.
PROALT presents at BIO 2017 International Convention in San Diego CA (USA) from 19 to 22 June. View more.
PROALT exhibits at BIOSPAIN 2016 organized by ASEBIO, the Spanish Bioindustry Association. View more.
PROALT project “Colodetect - Development of a novel blood-based diagnostic test for colorectal cancer” has been selected to receive funding from the EU Framework Programme Horizon 2020 SME Instrument. View more.
PROALT attends and exhibits at BIO 2015. View more.
PROALT in the media: El Mundo "El test low cost para detectar a tiempo el cáncer colorectal". View more.
PROALT has been finalist in The South Summit 2014. PROALT was selected within the 100 from more than 3000 startups from Southern Europe and South America and participated of the new global start up hub event THE SOUTH SUMMIT 2014 on October 8-10. View more.
PROALT presents its R&D activity in the field of early diagnosis of colorectal cancer during the Symposium on Cancer and Regenerative Medicine organized by Madrid Network in collaboration with UC Davis. View more.
PROALT enters into an agreement with Acris Antibodies GmbH to distribute ProAlt’s recombinant proteins and antibodies. German company Acris Antibodies is currently a global player in the research product / antibody market. Acris Antibodies Inc. branch office in San Diego, USA serves our products to customers within the United States, Canada, Mexico, Central and South America. View more.
PROALT participates in the biannual meeting of the working group COLOMICS 2. View more.
PROALT launches its new Website with a renovated image, updated contents and information of its new products and services, included its ongoing line of research.
PROALT participates in the Colomics-2 Symposium "Molecular Basis and translational Research in colorectal cancer". View more.
PROALT presents in Bilbao in front of the Biochem Investors Forum its colorrectal cancer diagnosis project. View more.
PROALT inaugurates its new offices and R&D laboratories in Tres Cantos, Madrid. View more.